Elucidating the role of dose in the biopharmaceutics classification of drugs: The concepts of critical dose, effective in vivo solubility, and dose-dependent BCS

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 3188-3198

  Charkoftaki, Georgia ^a   Dokoumetzidis, Aristides ^a   Valsami, Georgia ^a   MacHeras, Panos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

BCS; critical dose; DDBCS; dose; effective in vivo solubility

Indexed keywords

DICLOFENAC; KETOPROFEN; METOPROLOL;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DOSE; DRUG PENETRATION; DRUG SOLUBILITY; IN VIVO STUDY; MATHEMATICAL MODEL; PRIORITY JOURNAL; SIMULATION;

BIOPHARMACEUTICS; DOSE-RESPONSE RELATIONSHIP, DRUG; INTESTINAL ABSORPTION; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 84867851507     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0815-4     Document Type: Article

References (69)

1. Dressman JB, Amidon GL, Fleisher D. Absorption potential: estimating the fraction absorbed for orally administered compounds. J Pharm Sci. 1985;74(5):588-9.
2. Macheras PE, Symillides MY. Toward a quantitative approach for the prediction of the fraction of dose absorbed using the absorption potential concept. Biopharm Drug Dispos. 1989;10(1):43-53.
3. Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res. 1996;13:1795-8.
4. Yu LX. An integrated model for determining causes of poor oral drug absorption. Pharm Res. 1999;16:1883-7.
5. Takano R, Kataoka M, Yamashita S. Integrating drug permeability with dissolution profile to develop IVIVC. Biopharm Drug Disp. 2012;doi: 10.1002/bdd.1792.
6. Amidon G, Lennarnas H, Shah V, Crison J. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413-29.
7. Guidance for Industry. Waiver of in vivo bioavailability and bioequivalence studies for immediate release solid oral dosage forms based on a biopharmaceutics classification system. Washington, D.C.: CDER/FDA; 2000.
8. Yazdanian M, Briggs K, Jankovsky C, Hawi A. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res. 2004;21(2):293-9.
9. Rinaki E, Dokoumetzidis A, Valsami G, Macheras P. Identification of biowaivers among Class II drugs: theoretical justification and practical examples. Pharm Res. 2004;21(9):1567-72.
10. Rinaki E, Valsami G, Macheras P. Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. Pharm Res. 2003;20(12):1917-25.
11. Wu CY, Benet LZ. Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res. 2005;22(1):11-23.
12. EMA (European Medicines Agency). Committee for Medicinal Products for Human Use, CHMP. Guideline on the Investigation of Bioequivalence, London. 2010.
13. Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-47.
14. Broccatelli F, Cruciani G, Benet LZ, Oprea TI. BDDCS Class prediction for new molecular entities. Mol Pharm. 2012;9(3):570-80.
15. Oh DM, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res. 1993;10(2):264-70.
16. Yu LX, Crison JR, Amidon GL. Compartmental transit and dispersion model analysis of small intestinal transit flow in humans. Int J Pharm. 1996;140(1):111-8.
17. Benet LZ. Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. Basic Clin Pharmacol Toxicol. 2010;106(3):162-7.
18. Benet LZ, Larregieu CA. The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. Clin Pharmacol Ther. 2010;88(3):405-7.
19. Macheras P, Argyrakis P. Gastrointestinal drug absorption: is it time to consider heterogeneity as well as homogeneity? Pharm Res. 1997;14(7):842-7.
20. Dokoumetzidis A, Macheras P. IVIVC of controlled release formulations: physiological-dynamical reasons for their failure. J Control Release. 2008;129(2):76-8.
21. GastroPlus™ Simulation Plus inc. Available from: http://www.simulations-plus.com/Products.aspx?grpID=3&cID=16&pID=11.
22. SimCyp®, Population-based pharmacokinetic modeling and simulation. Available from: http://www.simcyp.com.
23. PK-Sim® Available from: http://www.systems-biology.com/products/pk- sim.html.
24. Wuelfing WP, Kwong E, Higgins J. Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets. Mol Pharm. 2012;7;9(5):1163-74.
25. Ding X, Rose JP, Van Gelder J. Developability assessment of clinical drug products with maximum absorbable doses. Int J Pharm. 2012;427(2):260-9.
26. Abu-Diak OA, Jones DS, Andrews GP. Understanding the performance of melt-extruded poly(ethylene oxide)-bicalutamide solid dispersions: characterisation of microstructural properties using thermal, spectroscopic and drug release methods. J Pharm Sci. 2012;101(1):200-13.
27. Cockshott ID, Oliver SD, Young JJ, et al. The effect of food on the pharmacokinetics of the bicalutamide (Casodex) enantiomers. Biopharm Drug Disp. 1997;18(6):499-507.
28. Cockshott ID. Bicalutamide. Clinical pharmacokinetics and metabolism. Clin Pharmacok. 2004;43(13):855-78.
29. Willis JV, Kendall MJ, Flinn RM, Thornhill DP, Welling PG. The pharmacokinetics of diclofenac sodium following intravenous and oral administration. Eur J Clin Pharmacol. 1979;16(6):405-10.
30. Leucuţa A, Vlase L, Farcau D, Nanulescu M. No effect of short term ranitidine intake on diclofenac pharmacokinetics. Rom J Gastroenterol. 2004;13(4):306-8.
31. Hinz B, Hug AM, Fotopoulos G, Gold MS. Bioequivalence study of low-dose diclofenac potassium tablet formulations. Int J Clin Pharmacol Ther. 2009;47(10):643-8.
32. De Bernardi di Valserra M, Feletti F, Bertè F, Nazzari M, Cenedese A, Cornelli U. Lack of effect of a single-dose of sulglicotide on the bioavailability of diclofenac. Eur J Clin Pharmacol. 1988;34(2):211-2.
33. Biasia G, Canova N, Palazzini E, Marcolongo R. Comparative pharmacokinetic study of a single dose of two prolonged-release formulations of diclofenac in healthy subjects. Current Ther Res. 1998;59(1):785-92.
34. Llinàs A, Burley JC, Box KJ, Glen RC, Goodman JM. Diclofenac solubility: independent determination of the intrinsic solubility of three crystal forms. Med Chem. 2007;50(5):979-83.
35. Shohin I, Kulinich J, Ramenskaya GV, Vasilenko GF. Evaluation of in vitro equivalence for drugs containing BCS class II compound ketoprofen. Dissol Tech. 2011;18:26-9.
36. Geisslinger G, Menzel S, Wissel K, Brune K. Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate. Br J Clin Pharmacol. 1995;40:73-5.
37. Jamali F, Brocks DR. Clinical pharmacokinetics of ketoprofen and its enantiomers. Clin Pharmacokinet. 1990;19(3):197-217.
38. Papadopoulou V, Valsami G, Dokoumetzidis A, Macheras P. Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. Int J Pharm. 2008;361:70-7.
39. Weitschies W, Wedemeyer RS, Kosch O, Fach K, Nagel S, Söderlind E, Trahms L, Abrahamsson B, Mönnikes H. Impact of the intragastric location of extended release tablets on food interactions. J Control Release. 2005;108(2-3):375-85.
40. Macheras P, Koupparis M, Antimisiaris S. Drug binding and solubility in milk. Pharm Res. 1990;7(5):537-41.
41. Galia E, Nicolaides E, Hoerter D, Loebenberg R, Reppas C, Dressman J. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15(5):698-705.
42. Charkoftaki G, Kytariolos J, Macheras P. Novel milk-based oral formulations: proof of concept. Int J Pharm. 2010;390(2):150-9.
43. Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman J, Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res. 2006;23(1):1373-81.
44. Brouwers J, Tack J, Augustijns P. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation. Int J Pharm. 2007;336(2):302-9.
45. Clarysse S, Psachoulias D, Brouwers J, Tack J, Annaert P, Duchateau G, Reppas C, Augustijns P. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS Class II drugs. Pharm Res. 2009;26(6):1456-66.
46. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP, Vogelpoel H, Bardens DM. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121-31.
47. Jantratid E, Prakongpan S, Dressman JB, Amidon GL, Junginger HE, Midha KK, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. J Pharm Sci. 2006;95(5):974-84.
48. Chuasuwan B, Binjedoh V, Polli JE, Zhang H, Amidon GL, Junginger HE, Shah MKK, et al. Biowaiver monographs for immediate release solid oral dosage forms: diclofenac sodium and diclofenac potassium. J Pharm Sci. 2009;98(4):1206-19.
49. Becker C, Dressman JB, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S. Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: rifampicin. J Pharm Sci. 2009;98(7):2252-67.
50. Bookstaver BP, Miller AD, Rudisill CN, Norris B. Intravenous ibuprofen: the first injectable product for the treatment of pain and fever. J Pain Res. 2010;3:67-79.
51. Gillespie WR, DiSanto AR, Monovich RE, Albert KS. Relative bioavailability of commercially available ibuprofen oral dosage forms in humans. J Pharm Sci. 1982;71(9):1034-8.
52. Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. The relationship between the pharmacokinetics of ibuprofen enantiomers and the dose of racemic ibuprofen in humans. Biopharm Drug Dispos. 1990;11(6):507-18.
53. Potthast H, Dressman JB, Junginger HE, Midha KK, Oeser H, Shah VP et al. Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. J Pharm Sci. 2005;94(10):2121-2131.33.
54. Henwood SQ, de Villiers MM, Liebenberg W, Lötter AP. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm. 2000;26(4):403-8.
55. Pähkla R, Lambert J, Ansko P, Winstanley P, Davies PD, Kiivet RA. Comparative bioavailability of three different preparations of rifampicin. J Clin Pharm Ther. 1999;24(3):219-25.
56. Chik Z, Basu RC, Pendek R, Lee TC, Mohamed Z. A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers. Clin Ther. 2010;32(10):1822-31.
57. Rafiq S, Iqbal T, Jamil A, Khan FH. Pharmacokinetic studies of rifampicin in healthy volunteers and tuberculosis patients. Int J Agric Biol. 2010;12:391-5.
58. Ruslami R, Nijland MJH, Alisjahbanaa B, Parwati I, van Crevel R, Rob AE. Pharmacokinetics and tolerability of a higher rifampin dose versus the standard dose in pulmonary tuberculosis patients. Antimicrob Agents Chemother. 2007;51(7):2546-51.
59. He BX, Shi L, Qiu J, Zeng XH, Tao L, Li R, Hong CJ, Gu XL, Dong FY, Yang L, Zhao SJ. Quantitative determination of atorvastatin and ortho-hydroxy atorvastatin in human plasma by liquid chromatography tandem mass spectrometry and pharmacokinetic evaluation. Methods Find Exp Clin Pharmacol. 2010;32(7):481-7.
60. Liu YM, Pu HH, Liu GY, Jia JY, Weng LP, Xu RJ, Li GX, Wang W, Zhang MQ, Lu C, Yu C. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males. Clin Ther. 2010;32(7):1396-407.
61. Rao N, Dvorchik B, Sussman N, Wang H, Yamamoto K, Mori A, Uchimura T, Chaikin P. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin. J Clin Pharmacol. 2008;48(9):1092-8.
62. Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S, Fujimura A. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60(5):494-7.
63. Arunkumar N, Venkateskumar K, Deecaraman M, Rani C, Mohanraj KP. Preparation and solid state characterization of atorvastatin nanosuspensions for enhanced solubility and dissolution. Int J PharmTech Research. 2009;1(4):1725-30.
64. Faasen F, Vromans H. Biowaivers for oral immediate-release products. Implications of linear pharmacokinetics. Clin Pharmacokinet. 2004;43(15):1117-26.
65. Szpunar GJ, Albert KS, Bole GG, Dreyfus JN, Lockwood GF, Wagner JG. Pharmacokinetics of flubiprofen in man. I. Area/dose relationships. Biopharm Drug Dispos. 1987;8(3):273-83.
66. Nash JF, Bechtol LD, Bunde CA, Bopp RJ, Farid KZ, Spradlin CT. Linear pharmacokinetics of orally administered fenoprofen calcium. J Pharm Sci. 1979;68(9):1087-90.
67. McAllister WA, Winfield CR, Collins JV. Pharmacokinetics of prednisolone in normal and asthmatic subjects in relation to dose. Eur J Clin Pharmacol. 1981;20(2):141-5.
68. Bauer-Brandl A. Polymorphic transitions of cimetidine during manufacture of solid dosage forms. Int J Pharmaceutics. 1996;140(2):195-206.
69. Grahnén A, Bahr C, Lindström B, Rosén A. Bioavailability and pharmacokinetics of cimetidine. Eur J Clin Pharmacol. 1979;16(5):335-40.